Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.55 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495647 | 0.89 | RAD52 (0.48) | HPGDSCHRM4 | |
| SCHEMBL16495621 | 0.88 | HPGDS (0.60) | HPGDSCHRM4 | |
| SCHEMBL16495443 | 0.86 | HPGDS (0.62) | HPGDSACHECHRM4 | |
| SCHEMBL16495798 | 0.83 | SLC6A2 (0.58) | HPGDSBAZ2BUSP30 | |
| SCHEMBL2069780 | 0.83 | HPGDS (0.69) | HPGDSBAZ2BUSP30 | |
| SCHEMBL16495852 | 0.78 | MEN1 (0.60) | HPGDSBAZ2B | |
| SCHEMBL16495873 | 0.78 | HPGDS (0.54) | HPGDSBAZ2BUSP30 | |
| SCHEMBL16495438 | 0.77 | MEN1 (0.59) | HPGDSBAZ2B | |
| SCHEMBL16496176 | 0.77 | MAP4K4 (0.58) | HPGDS | |
| SCHEMBL17888463 | 0.76 | NPSR1 (0.57) | ACHECHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885BAZ2B 1779/4885USP30 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.